Golub Capital BDC enters the back half of August with two signals pointing in the same direction: a tightening lending market and fresh insider selling that leaves bulls leaning on a thin valuation cushion.
The borrow story is the most immediate tension. Availability has dropped to roughly 10% — meaning only one share remains lendable for every nine already out on loan. That is tight, and has been trending that way. At the most extreme point in late July, availability briefly touched just 1.2%, the tightest level of the past year, before recovering modestly. The cost to borrow has been running in the 6%–7% range for weeks, a level that prices in meaningful bearish conviction. Short interest in absolute terms is now around 12 million shares, essentially unchanged on the month after a period of heavier covering through late July and early August. Options add another layer of caution: the put/call ratio is running at 2.37, well above its 20-day average of 2.12, a reading roughly 1.7 standard deviations elevated. Taken together, the lending and options markets are both reflecting defensive positioning, though the borrow has loosened enough from July's near-zero availability to suggest the most acute pressure may have passed.
The insider flow is harder to dismiss. On August 7, GEMS FUND 4, LP — a family holding entity — sold 1.67 million shares at $13.06 per share, a transaction worth just under $22 million. That follows a much larger affiliated sale in May 2025, when GCOP LLC disposed of 3.86 million shares. These are not open-market executive trades, but they are material in size relative to GBDC's float. Notably, GCOP LLC also appears in the top institutional holders list, having reported a fresh 3.48 million-share position as of August 7 — the same date as the GEMS FUND sale — suggesting a restructuring of affiliated exposure rather than outright exit. The net 90-day insider flow registers as a sell of 1.68 million shares, a signal worth tracking even if the mechanics are complex.
The Street has been moving in one direction on price targets, though ratings have held. Keefe, Bruyette & Woods trimmed its target to $13.50 from $14.00 on August 5, maintaining Outperform. RBC Capital cut its target earlier in May to $14.00 from $15.00, also keeping Outperform. Both firms remain constructive on the name, but the gap between the highest recent target ($14.00) and the current price of $13.07 has narrowed considerably — leaving limited implied upside on the most optimistic current views. The stock trades at 0.93x book and 10.1x earnings, multiples that have edged higher over the past month. The ORTEX short score is running at 70.9 — solidly in bearish territory — though it has been stable rather than accelerating over the past two weeks.
GBDC is underperforming most of its BDC peer group on the week. ARCC fell 1.5% over the same period, OBDC dropped 2.3%, and NMFC slid 3.6%. OCSL was the notable exception, gaining 1% on the week. The sector-wide softness makes GBDC's own 0.8% weekly decline look less company-specific — though the combination of tight availability, elevated options hedging, and continued affiliated selling distinguishes its setup from the broader group.
The next scheduled earnings date is November 23. Between now and then, the key gauge is whether borrow availability continues to drift back toward the normalised range above 20%, or whether another round of affiliated selling tightens it again toward the July lows.
See the live data behind this article on ORTEX.
Open GBDC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
